Nextage Therapeutics Stock Target Price
| MCTC Stock | ILA 81.00 1.90 2.29% |
Nextage Therapeutics fundamentals help investors to digest information that contributes to Nextage Therapeutics' financial success or failures. It also enables traders to predict the movement of Nextage Stock. The fundamental analysis module provides a way to measure Nextage Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nextage Therapeutics stock.
Nextage |
Nextage Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nextage Therapeutics' direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nextage Therapeutics could also be used in its relative valuation, which is a method of valuing Nextage Therapeutics by comparing valuation metrics of similar companies.Nextage Therapeutics is currently under evaluation in target price category among its peers.
Nextage Fundamentals
| Return On Asset | -0.37 | |||
| Profit Margin | (2.30) % | |||
| Operating Margin | (9.71) % | |||
| Shares Outstanding | 2.27 M | |||
| Shares Owned By Insiders | 22.39 % | |||
| Shares Owned By Institutions | 0.02 % | |||
| Price To Earning | (91.98) X | |||
| Price To Book | 4.68 X | |||
| Price To Sales | 26.11 X | |||
| Revenue | 297 K | |||
| Gross Profit | 207 K | |||
| EBITDA | (5.38 M) | |||
| Net Income | (2.09 M) | |||
| Cash And Equivalents | 358 K | |||
| Cash Per Share | 0.16 X | |||
| Debt To Equity | 65.70 % | |||
| Current Ratio | 0.44 X | |||
| Book Value Per Share | 0.90 X | |||
| Cash Flow From Operations | (5 M) | |||
| Earnings Per Share | (0.24) X | |||
| Beta | 1.05 | |||
| Market Capitalization | 9.54 M | |||
| Total Asset | 6.01 M | |||
| Retained Earnings | (103 M) | |||
| Working Capital | 1000 K | |||
| Current Asset | 3 M | |||
| Current Liabilities | 2 M | |||
| Z Score | -23.8 | |||
| Net Asset | 6.01 M |
About Nextage Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nextage Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nextage Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nextage Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Nextage Stock
Nextage Therapeutics financial ratios help investors to determine whether Nextage Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nextage with respect to the benefits of owning Nextage Therapeutics security.